EDUCATION > Courses and Products > E-Learning > Videos/Webcasts > 2012 Annual Meeting Webcasts > Advanced Prostate Cancer > Module 2: Androgen Deprivation Therapy and the Treatment of Advanced Prostate Cancer

Module 2: Androgen Deprivation Therapy and the Treatment of Advanced Prostate Cancer

Activity Description

This activity will discuss the basics of the metabolic syndrome and its origins, discuss how to initiate an androgen deprivation therapy (ADT) clinic to monitor and address these issues, and the potential role of new hormonal agents in the treatment of advanced prostate cancer.

Learning Objectives

After participating in this activity, participants should be able to:
  • describe the background of the use of ADT and all its metabolic side effects
  • diagnose and treat bone loss associated with ADT
  • examine cardiovascular side effects and appropriate monitoring
  • introduce new hormonal therapies/strategies for advanced prostate cancer

Faculty/Authors

Paul R. Sieber, MD, Course Director
Urological Associates of Lancaster
Lancaster, PA
Disclosures: Wilex: Scientific Study or Trial ; Spectrum: Scientific Study or Trial ; Nymox: Scientific Study or Trial ; Sanofi Synthelabo: Scientific Study or Trial ; GTX: Health Publishing,Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; POM Wonderful: Scientific Study or Trial ; Bavarian Nordic: Scientific Study or Trial ; Medivation/Astellas: Scientific Study or Trial ; ENDO: Scientific Study or Trial ; Ferring: Meeting Participant or Lecturer,Scientific Study or Trial ; Amgen: Health Publishing,Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; watson: Consultant or Advisor,Meeting Participant or Lecturer,Scientific Study or Trial ; Auxillium: Consultant or Advisor,Scientific Study or Trial ; Millenium: Scientific Study or Trial ; ActiveBiotech: Scientific Study or Trial

Stephen J. Freedland, MD
Associate Professor
Duke University
Durham, NC
Disclosures: AstraZeneca: Consultant or Advisor,Meeting Participant or Lecturer ; Amgen: Consultant or Advisor,Meeting Participant or Lecturer ; GSK: Scientific Study or Trial ; Dendreon: Consultant or Advisor ; Medivation: Consultant or Advisor ; Centocor Ortho Biotech: Consultant or Advisor,Meeting Participant or Lecturer ; Bayer: Consultant or Advisor ; Mitomics: Consultant or Advisor

Neal D. Shore, MD
Research Director
Carolina Urologic Research Institute
Myrtle Beach, NC
Disclosures: GP Pharma: Consultant or Advisor ; Uroplasty, Inc.: Consultant or Advisor ; Astellas: Consultant or Advisor ; Nymox: Consultant or Advisor ; amgen: Consultant or Advisor ; dendreon: Consultant or Advisor ; Medivation: Consultant or Advisor ; Sanofi: Consultant or Advisor ; Janssen: Consultant or Advisor ; Bayer: Consultant or Advisor

Acknowledgement for Support

Support provided by educational grants from the following companies:

AMGEN Astellas Janseen
Medivation Millennium



Guise TA, et al. Rev Urol. 2007;9:163-180.

Higano CS. Nat Clin Pract Urol. 2008;5:24-34, copyright 2008. Reprinted by permission.

Hussain SA BJU 92(7);690-4 Nov 2003

Kannegaard Age and Aging 39:203-209 Jan 2010

Planas J BJU Int 99812-816 2007

Shahinian VB, Kuo YF, Freeman JL, Goodwin JS. Risk of fracture after androgen deprivation for prostate cancer. N Engl J Med. 2005;352:154-164.

Smith MR, Cancer1 91(12);2238-2245 2001

Tanvetyanon,Cancer 103(2):237-241 Jan 2005

ADVERTISEMENT

ADVERTISEMENT
Donate
Contact
Press/Media
Sections
Term of Use
Site Map


ADVERTISEMENT